<DOC>
	<DOCNO>NCT01068951</DOCNO>
	<brief_summary>The main hypothesis investigator study development autoimmune diabetes may halt att diagnosis immune modulatory property mesenchymal stem cell .</brief_summary>
	<brief_title>Treatment Patients With Newly Onset Type 1 Diabetes With Mesenchymal Stem Cells</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Ability provide write informed consent Mentally stable able comply procedure study protocol Clinical history compatible type 1 diabetes diagnose less 10 day enrolment Stimulate cpeptide &gt; 0.1 nmol/l Patients BMI &gt; 30 Patients unstable cardiovascular status Patients active infection , unless treatment judge necessary investigator Patients serological evidence infection HIV , hepatitis B hepatitis C. Sexually active female ) postmenopausal , b ) surgically sterile c ) use acceptable method contraception : oral contraceptive , Norplant , Depoprovera barrier device combine spermicidal gel acceptable . Patients know previous malignancy . Patient condition circumstance opinion investigator would make unsafe undergo treatment autologous MSC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>mesenchymal stem cell</keyword>
	<keyword>intervention</keyword>
</DOC>